Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

The introduction of molecularly targeted therapies with tyrosine kinase inhibitors has revolutionized cancer therapy and has contributed to a steady decline in cancer-related mortality since the late 1990s. However, not only cardiac but also vascular toxicity has been reported for these agents, some as expected on-target effects (e.g., VEGF receptor inhibitors) and others as unanticipated events (e.g., BCR-Abl inhibitors). A sound understanding of these cardiovascular toxic effects is critical to advance mechanistic insight into vascular disease and clinical care. From a conceptual standpoint, there might be value in defining type I (permanent) and type II (transient) vascular toxicity. This review will focus on the tyrosine kinase inhibitors in current clinical use and their associated vascular side effects.

Original languageEnglish (US)
Article number33
JournalCurrent Oncology Reports
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Protein-Tyrosine Kinases
Blood Vessels
Vascular Endothelial Growth Factor Receptor
Poisons
Vascular Diseases
Neoplasms
Mortality
Therapeutics

Keywords

  • Angina
  • Cancer
  • Cardiomyopathy
  • Chemotherapy
  • Endothelial dysfunction
  • Myocardial infarction
  • Stroke
  • Thrombosis
  • Vasospasm

ASJC Scopus subject areas

  • Oncology

Cite this

Tyrosine Kinase Inhibitors and Vascular Toxicity : Impetus for a Classification System? / Herrmann, Joerg.

In: Current Oncology Reports, Vol. 18, No. 6, 33, 01.06.2016.

Research output: Contribution to journalReview article

@article{8ce4b3563b5f446da6e7730aef30a5a4,
title = "Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?",
abstract = "The introduction of molecularly targeted therapies with tyrosine kinase inhibitors has revolutionized cancer therapy and has contributed to a steady decline in cancer-related mortality since the late 1990s. However, not only cardiac but also vascular toxicity has been reported for these agents, some as expected on-target effects (e.g., VEGF receptor inhibitors) and others as unanticipated events (e.g., BCR-Abl inhibitors). A sound understanding of these cardiovascular toxic effects is critical to advance mechanistic insight into vascular disease and clinical care. From a conceptual standpoint, there might be value in defining type I (permanent) and type II (transient) vascular toxicity. This review will focus on the tyrosine kinase inhibitors in current clinical use and their associated vascular side effects.",
keywords = "Angina, Cancer, Cardiomyopathy, Chemotherapy, Endothelial dysfunction, Myocardial infarction, Stroke, Thrombosis, Vasospasm",
author = "Joerg Herrmann",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s11912-016-0514-0",
language = "English (US)",
volume = "18",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Tyrosine Kinase Inhibitors and Vascular Toxicity

T2 - Impetus for a Classification System?

AU - Herrmann, Joerg

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The introduction of molecularly targeted therapies with tyrosine kinase inhibitors has revolutionized cancer therapy and has contributed to a steady decline in cancer-related mortality since the late 1990s. However, not only cardiac but also vascular toxicity has been reported for these agents, some as expected on-target effects (e.g., VEGF receptor inhibitors) and others as unanticipated events (e.g., BCR-Abl inhibitors). A sound understanding of these cardiovascular toxic effects is critical to advance mechanistic insight into vascular disease and clinical care. From a conceptual standpoint, there might be value in defining type I (permanent) and type II (transient) vascular toxicity. This review will focus on the tyrosine kinase inhibitors in current clinical use and their associated vascular side effects.

AB - The introduction of molecularly targeted therapies with tyrosine kinase inhibitors has revolutionized cancer therapy and has contributed to a steady decline in cancer-related mortality since the late 1990s. However, not only cardiac but also vascular toxicity has been reported for these agents, some as expected on-target effects (e.g., VEGF receptor inhibitors) and others as unanticipated events (e.g., BCR-Abl inhibitors). A sound understanding of these cardiovascular toxic effects is critical to advance mechanistic insight into vascular disease and clinical care. From a conceptual standpoint, there might be value in defining type I (permanent) and type II (transient) vascular toxicity. This review will focus on the tyrosine kinase inhibitors in current clinical use and their associated vascular side effects.

KW - Angina

KW - Cancer

KW - Cardiomyopathy

KW - Chemotherapy

KW - Endothelial dysfunction

KW - Myocardial infarction

KW - Stroke

KW - Thrombosis

KW - Vasospasm

UR - http://www.scopus.com/inward/record.url?scp=84964222437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964222437&partnerID=8YFLogxK

U2 - 10.1007/s11912-016-0514-0

DO - 10.1007/s11912-016-0514-0

M3 - Review article

C2 - 27099141

AN - SCOPUS:84964222437

VL - 18

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 6

M1 - 33

ER -